OR WAIT null SECS
GoSilico’s software for digital twins of downstream biopharmaceutical processes will be integrated into Cytiva.
Cytiva has acquired the German scientific software maker GoSilico, the company announced in a June 2, 2021 press release. GoSilico’s simulation software is used to build digital twins of downstream processing to speed process development using mechanistic modelling to replace physical experiments.
“The powerfully innovative digital solution created by GoSilico will bring great value to our customers, who can use mechanistic models to improve their decisions, accelerate their process development, and more quickly bring new therapies to market,” said Olivier Loeillot, vice-president, Cytiva, in the press release.
“Our entire team is excited to join the Cytiva family. With Cytiva’s global presence and broad base of customers, our mechanistic modelling technology will reach more drugmakers, ultimately enabling a more robust process development and a more efficient path to bring new therapies to patients,” said Thiemo Huuk, co-founder and co-CEO of GoSilico, in the press release.
Traditional process development methods are time consuming. “One factor at a time” can take approximately 13 weeks and design of experiments often takes approximately four weeks, but simulation using modelling in digital twins can be a scalable and robust solution within about one week, Cytiva said in the press release. In addition, modeling reduces the amount of experiment materials used.
GoSilico’s products will continue to be known as GoSilico ChromX and GoSilico DSPX for the immediate future and will be integrated into Cytiva immediately, according to the press release.